GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chemomab Therapeutics Ltd (NAS:CMMB) » Definitions » Return-on-Tangible-Asset

CMMB (Chemomab Therapeutics) Return-on-Tangible-Asset : -89.28% (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Chemomab Therapeutics Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Chemomab Therapeutics's annualized Net Income for the quarter that ended in Mar. 2025 was $-13.29 Mil. Chemomab Therapeutics's average total tangible assets for the quarter that ended in Mar. 2025 was $14.89 Mil. Therefore, Chemomab Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was -89.28%.

The historical rank and industry rank for Chemomab Therapeutics's Return-on-Tangible-Asset or its related term are showing as below:

CMMB' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -80.5   Med: -51.49   Max: -32.49
Current: -80.5

During the past 5 years, Chemomab Therapeutics's highest Return-on-Tangible-Asset was -32.49%. The lowest was -80.50%. And the median was -51.49%.

CMMB's Return-on-Tangible-Asset is ranked worse than
73.1% of 1498 companies
in the Biotechnology industry
Industry Median: -36.17 vs CMMB: -80.50

Chemomab Therapeutics Return-on-Tangible-Asset Historical Data

The historical data trend for Chemomab Therapeutics's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chemomab Therapeutics Return-on-Tangible-Asset Chart

Chemomab Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
-47.75 -32.49 -51.49 -74.31 -71.33

Chemomab Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -77.07 -89.23 -78.62 -62.62 -89.28

Competitive Comparison of Chemomab Therapeutics's Return-on-Tangible-Asset

For the Biotechnology subindustry, Chemomab Therapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chemomab Therapeutics's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chemomab Therapeutics's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Chemomab Therapeutics's Return-on-Tangible-Asset falls into.


;
;

Chemomab Therapeutics Return-on-Tangible-Asset Calculation

Chemomab Therapeutics's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-13.945/( (22.143+16.957)/ 2 )
=-13.945/19.55
=-71.33 %

Chemomab Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=-13.292/( (16.957+12.819)/ 2 )
=-13.292/14.888
=-89.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2025) net income data.


Chemomab Therapeutics  (NAS:CMMB) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Chemomab Therapeutics Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Chemomab Therapeutics's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Chemomab Therapeutics Business Description

Traded in Other Exchanges
Address
Kiryat Atidim, Building 7, Tel Aviv, ISR, 6158002
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
Executives
Orbimed Israel Biofund Gp Limited Partnership 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629
George Adi Mor director, 10 percent owner, officer: Chief Executive Officer 15 KAFRISIN ST., TEL AVIV L3 6901658
Neil Harris Cohen director C/O ANCHIANO THERAPEUTICS LTD., ONE KENDALL SQ., BLDG 1400E, STE 14-105, CAMBRIDGE MA 02139
Matthew Bejosa Frankel officer: Chief Medical Officer 672 PROSPECT AVE., PRINCETON NJ 08540
Jill M. Quigley director TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103
Joel Michael Maryles director 5 ATZMON ST., HASHMONAIM L3 7312700
Donald Marvin officer: Executive VP, CFO & COO 2094 LOST CANYON RANCH CT, CASTLE ROCK CO 80104
Dale R Pfost director, officer: Chief Executive Officer ACUITY PHARMACEUTICALS INC, 3701 MARKET STREET, PHILADELPHIA PA 19104
Nissim Darvish director C/O INNOVATE BIOPHARMACEUTICALS, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Peter Thiel 10 percent owner 9200 SUNSET BOULEVARD, SUITE 1110, WEST HOLLYWOOD CA 90069
Sigal Fatal officer: Chief Financial Officer 16 KANFEY NESHARIM ST., RAMAT GAN L3 5235716
Arnon Aharon officer: Chief Medical Officer 12 YAVNE ST., TEL AVIV L3 6579116
Alan Charles Moses director C/O 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Stephen P Squinto director C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Orbimed Israel Gp Ltd. 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629